Manufacturing live biotherapeutic product is bothtechnically challenging and financially demanding; as a result, innovator firmsare becoming increasingly reliant on contract service providers to accessspecialized facilities and optimize overall costs.
Roots Analysis is pleased toannounce the publication of its recent study, titled, “LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market,2020-2030: Focus on Active Pharmaceutical Ingredients and Finished DosageForms, 2020-2030.”
The report features an extensive study of thecurrent landscape and future opportunities related to contract services formicrobiome therapeutics. The study features an in-depth analysis, highlightingthe capabilities of a diverse set of contract service providers, including CMOsand CDMOs. Amongst other elements, the report includes:
§ Adetailed review of the overall landscape of companies offering contractservices for manufacturing of microbiome therapeutics.
§ Alist of companies with in-house manufacturing facilities for microbiometherapeutics.
§ Elaborateprofiles of key industry players (large and mid-sized companies, establishedbefore 2000) based in North America, Europe and Asia-Pacific.
§ Anassessment of microbiome contract manufacturing capability in differentregions.
§ Alist of nearly 50 microbiome-focused drug developers that are anticipated topartner with contract manufacturers.
§ Adetailed clinical trial analysis of more than 150 completed, ongoing andplanned studies of various microbiome therapeutics sponsored by both industryand non-industry players.
§ Anestimate of the overall, installed capacity for manufacturing of microbiometherapeutics, taking into consideration the capabilities of variousstakeholders.
§ An informedestimate of the annual clinical demand for microbiome therapeutics, taking intoaccount the target patient population in ongoing and planned clinical trials ofmicrobiome therapeutics, sponsored by both industry and non-industry players.
§ Aqualitative analysis, highlighting the various factors that need to be takeninto consideration by microbiome therapeutics developers while deciding whetherto manufacture their respective products in-house or engage the services of aCMO.
§ Areview of the varied microbiome-focused initiatives of big pharma players.
A detailed market forecast,featuring analysis of the current and projected future opportunity across keymarket segments (listed below):
§ Type of ProductManufactured
§ Active PharmaceuticalIngredients (APIs)
§ Finish DrugFormulations (FDFs)
§ Type of Type ofFormulation
§ Solid Formulations
§ Oral Liquids
§ Scale of Operation
§ Company Size
§ Key GeographicalRegions
§ North America
§ Asia-Pacific and Restof the World
Keycompanies covered in the report
§ BJP Laboratories
§ Capsugel (acquired byLonza)
§ Cobra Biologics(acquired Cognate Bioservices)
§ Inpac Probiotics
§ ParagonBioservices (a unit of Catalent Biologics)
§ UAS Labs
Formore information please click on the following link:
Other Recent Offerings
1. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
2. Antibody Contract Manufacturing Market, 2020 – 2030
3. The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targetingdrugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in the bio-pharmaceuticalindustry. The in-depth research, analysis and insights are driven by anexperienced leadership team which has gained many years of significantexperience in this sector. If you’d like help with your growing business needs,get in touch at firstname.lastname@example.org
Roots Analysis Private Limited
+1 (415) 800 3415